The Conversation (0)
Aimmune Therapeutics, a biotech company that is developing an oral immunotherapy intended to decrease the effects of peanut allergies, announced the terms for its IPO.
Aimmune Therapeutics, a biotech company that is developing an oral immunotherapy intended to decrease the effects of peanut allergies, announced the terms for its IPO.
According to the announcement on Renaissance Capital IPO Center:
The Brisbane, CA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Aimmune Therapeutics would command a market value of $585 million.
Aimmune Therapeutics, which was founded in 2011, plans to list on the Nasdaq under the symbol AIMT. BofA Merrill Lynch, Credit Suisse and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of August 3, 2015.
Click here to read the full article on Renaissance Capital IPO Center.
Â